4sc Ag

American Cyanamid Company

Basf Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Wyeth

Ortho-mcneil Pharmaceutical Corp.

Takeda Gmbh

Azad Pharma Ag

Astrazeneca Ab

Bayer Cropscience Ag

Consortium Fur Elektrochemische Industrie Gmbh

Nycomed Gmbh

Alfred E. Tiefenbacher Gmbh & Co. Kg

4sc Discovery Gmbh

Thomas Maier

Stefan Scheiblich

Helmut Siegfried Baltruschat

Thomas Beckers

Astrid Zimmermann

Volker Gekeler

Thomas Baer

Matthias Vennemann

Thomas Bär

Petra Gimmnich

Axel Kleemann

Sanjeev Anant Kulkarni

Rolf-Peter Hummel

Hemant Joshi

Martin Feth

Sarvesh S Patel

Bernd Mueller

Christian Hesslinger

Steffen Weinbrenner

Bernd Müller

Thomas Ciossek

Gary Mitchell Karp

Ulf Bömer

Hartmut Rehwinkel

Gerhard Schnabel

Michael E Condon

Frank John Villani, Jr

Gerhard Frisch

Beate Schmidt

Dieter Flockerzi

Ulrich Kautz

Armin Hatzelmann

Ningshu Liu

Camille Georges Wermuth

Degenhard Marx

Stuart Ince

Hua M Zhong

Martin Viertelhaus

Ulrich Weigl

Hermann Tenor

Stefan Fischer

Bruce D Harris

Mathias Schmidt

Christof Zitt

Andreas Pahl

Ulrich Graedler

Josef Stadlwieser

Detlev Haase

Paola Ciapetti

Torsten Dunkern

Axel Kleeman

Armin Roessler

Jean-Marie Contreras

Matthias Müller

Joseph Luke Pont

Frank Dullweber

Swen Hölder

Armin Zülch

Hans-Peter Hofmann

Anil P Jagtap

Thomas Hoellmueller

Ganesh S Chaure

Jürgen Volz

Umesh Bhise

Sunil Chavan

Vikas Gore

Armin Zuelch

Thomas Stengel

Raimund Külzer

Clemens Braun

Alexander Weber

Ewald Benediktus

Ragna Hussong

Florian Dehmel

Siegfried Schneider

Yogesh Munot

Sachin Shivatare

Christoph Winterhalter

Fan Zhang-Plasket

Gerrit Beneke

Kristine Nerkararyan

Jürgen Braunger

Uday Joshi

Gudrun Groegor

Michael Breslav

Thekla Haselwander

Andreas Strub

Juergen Braunger

Kamlesh Padiya

Karine Barseghyan

Mahindra Makhija

Dipak Harel

Heike Rothfels

Kamlesh J Padiya

Davit Hambardzumyan

Birdella Kenney

Manuela Hessmann

Stephen Scheiblich

Grigor Gevorgyan

The present invention relates to a new path to synthesize crystalline Tafamidis polymorphs starting from a Tafamidis acetic acid adduct. In addition, this invention relates to a process to synthesize Tafamidis (2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid * (2R,3R,4R,5S)-6-(methyl-amino)-hexane-1,2,3,4,5-pentol), new Tafamidis crystalline polymorphs, a pharmaceutical compositions comprising the new crystalline polymorphs and to the therapeutic use of such new polymorphs.

Polymorphs and new path to synthesize Tafamidis

Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.

Substituted imidazoquinolines

Compounds of formula (I) a tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6 and R7 have the meanings as given in the description and the claims, are effective inhibitors of the Pi3K/Akt pathway.

Fused bicyclic imidazoles

The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.

3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives

Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors. 

Sulfonylpyrroles

Fused pyrimidines

N-sulphonylpyrroles and their use as histone deacetylase inhibitors

Process for the preparation of a compound of formula (I) wherein R1, R2, R3, R4, R5 and R6 have the meanings as defined in the specification, comprising the step of reacting an acrylic acid chloride compound of formula (II'): wherein R1, R2, R3, R4, R5 and R6 have the meanings as defined in the specification, with aqueous hydroxylamine and optionally converting the resulting compound into an acid addition salt thereof. 

Method for the production of sulphonylpyrroles as HDAC inhibitors

Compounds of a certain formula (I) wherein R1, R2, R3, X, Y, r, s, t, u and v have the meanings as defined in the specification, and the salts, solvates and hydrates thereof are novel effective HDAC 6 inhibitors. 

N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds

A salt of (E)-N-{2-amino-phenyl)-3-{1-[4-(1-methyl-1 H-pyrazol-4-yl)-be&#x3c0;zenesulfonyl]-1 H-pyrrol-3-yl)-acrylamide selected from the group consisting of the hydrobromide, methansulfonate, hemi ethane-1,2-disulfonate, benzenesulfonate, toiuenesulfonate and 2-naphthalenesulfonate.

(E)-N-(2-amino-phenyl)-3-{1-[4-(l-methyl-1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide salts

The compounds of formula (I), wherein ring D and ring E together form a fused ring system selected from formula (II), (III), (IV), (V), (VI), (VII), and the salts of these compounds are novel, effective inhibitors of histone deacetylases. 

Tetrahydro-fused pyridines as histone deacetylase inhibitors

Growing community of inventors

Stockach, Germany

Thomas Maier